Early access
Sign in
Taking people in Hong KongPhase 2

Tests NAD precursor supplements for vision in glaucoma patients

Tests daily oral NAD precursor supplements against placebo in adults with glaucoma.

Key facts

Who runs it
Christopher Kai Shun Leung
Where
Wong Chuk Hang, Hong KongSee the site
Trial code
Registry title
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Status
Recruiting
Phase
Phase 2
People taking part
138 people, planned
Started
19 May 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Nicotinamide Riboside
  • Nicotinamide
  • Nicotinamide Mononucleotide
  • Nicotinic Acid
  • Placebo (Corn Starch)
Record updated
26 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with glaucoma, treated with eye pressure under 21 mmHg. It tests whether daily NAD supplements for two weeks improve vision.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Glaucoma, with visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard.
Earlier treatment
People who used NAD precursor supplements in the 14 days before the start cannot join.

Main reasons for not taking part

  • Pathological myopia
  • Other diseases that may cause visual field loss or optic disc changes
  • Diabetic retinopathy or maculopathy
  • Abnormal liver function within the past 12 months
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • glaucoma patients
  • age ≥ 18 years
  • best corrected VA ≥20/40
  • IOP <21 mmHg
  • visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard

Who cannot take part

  • use of NAD precursor supplements 14 days prior to baseline
  • diseases that may cause visual field loss or optic disc abnormalities other than glaucoma
  • history of abnormal liver function within 12 months
  • known allergy to NAD precursor supplement(s)
  • pathological myopia
  • inability to perform reliable visual field
  • suboptimal quality of OCT images
  • diabetic retinopathy/maculopathy
  • pregnancy or lactation

Where in Hong Kong

  • HKU Eye CentreWong Chuk Hang, Hong KongContact: Kai-shun Christopher LEUNG, MDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are:

Read full original descriptionShow less

1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function?

Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo.

Participants will:

Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks.

Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks.

Provide blood samples before and after the intervention for measurement of NAD+ metabolites.

Have safety monitored through clinical examination.

This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.

The 6 groups in the trial

  • Nicotinamide Riboside (Phase I)Treatment being tested

    Treatment: Nicotinamide Riboside

  • Nicotinamide (Phase I)Existing treatment, for comparison

    Treatment: Nicotinamide

  • Nicotinamide Mononucleotide (Phase II)Existing treatment, for comparison

    Treatment: Nicotinamide Mononucleotide

  • Nicotinic Acid (Phase II)Existing treatment, for comparison

    Treatment: Nicotinic Acid

  • Placebo (Phase I)Placebo, for comparison

    Treatment: Placebo (Corn Starch)

  • Placebo (Phase II)Placebo, for comparison

    Treatment: Placebo (Corn Starch)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparisons of Nicotinamide Adenine Dinucleotide (NAD) Precursors for Neuroenhancement in Glaucoma Patients
Plain-language title
Tests NAD precursor supplements for vision in glaucoma patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 June 2025